As of November 7, 2026, Bambusa Therapeutics, Inc. is a publicly traded company (Nasdaq: BBTX). The largest holder reporting an active stake on Schedule 13D is RA Capital, at 14.6%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Thomas Maier (9.2%) (Schedule 13D, November 6, 2026).
Is this your company?
About to sign with, pay or invest in Bambusa Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Bambusa Therapeutics, Inc. a real, registered company?
- Bambusa Therapeutics, Inc. files with the SEC under CIK 2044950 (its SEC filings).
- Its shares are listed under the ticker BBTX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Bambusa Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names RA Capital (filed 2026-11-06).
Who are Bambusa Therapeutics, Inc.'s owners and officers?
Bambusa Therapeutics, Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13D, 2026-11-06).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director, Promoter (Form D, 2025-02-26)
- : Director (Form D, 2025-02-26)
- : Director (Form D, 2025-02-26)
- : Director (Form D, 2025-02-26)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D, 2026-11-06 | Ra Capital Management, L.P. | 14.6% |
| Schedule 13G, 2026-11-05 | Thomas Maier | 9.2% |
Questions about who owns Bambusa Therapeutics, Inc.
Who owns Bambusa Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Bambusa Therapeutics, Inc.: Ra Capital Management, L.P. (14.6%, Schedule 13D, filed 2026-11-06) and Thomas Maier (9.2%, Schedule 13G, filed 2026-11-05).
Who are the largest shareholders of Bambusa Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Bambusa Therapeutics, Inc. on this page are Ra Capital Management, L.P. (14.6%) and Thomas Maier (9.2%).
When did Ra Capital Management, L.P. buy into Bambusa Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13D, filed 2026-11-06, reporting 14.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Bambusa Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Bambusa Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bambusa Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Bambusa Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Salvia Investment GmbH, a 10% owner: 9,264,301 shares (Form 4, 2026-11-02).
- , a director and 10% owner: 9,264,301 shares, held indirectly (the form names the holder only in its footnotes) (Form 4, 2026-11-02).
- , a director and 10% owner: 7,562,518 shares, held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-02).
- MiNeng, Inc., a 10% owner: 7,562,518 shares, held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-02).
- RA Capital, a director and 10% owner: 1,495,971 shares, held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-03).
Shares only: the company's cover page does not give one share count for a single class, so no percentage is worked out.
How much has Bambusa Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-02-26 | $53.27M | $88.88M |
| Form D, 2025-01-08 | $9M | $9M |
| Form D, 2025-01-08 | $5.10M | $5.10M |
Latest IPO step: Bambusa Therapeutics, Inc. filed its final IPO prospectus, ticker BBTX (424B4, 2026-10-30).
IPO filings: 424B4, 2026-10-30, S-1/A, 2026-10-26, S-1, 2026-10-09; ticker BBTX on Nasdaq Global Select Market.
Keep reading
More on Bambusa Therapeutics, Inc. and the records around it.
The people at Bambusa Therapeutics, Inc.
- Derek DiRocco is also named on 1 other Form D filing: Stipple Bio, Inc. (Apr 2026)
Bambusa Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- ATHOS KG also filed stake reports on 1 other company: BioNTech SE (May 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: SOLID BIOSCIENCES INC. (Nov 2026), LENZ THERAPEUTICS, INC. (Nov 2026), Alector, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/bambusa-therapeutics